Loading
NASDAQHealthcareBiotechnology
Latest quote
$16.99
+$0.09 · +0.53%
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Latest quote
$16.99
+$0.09 · +0.53%
After-hours
$17.09
+$0.10 · +0.59%
Oct 9, 5:22 PM ET
Regular session · ET · Market data may be delayed.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Day range
Current $16.99
52-week range
Current $16.99
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
30
Expensive
Sentiment
60
Mixed
Risk
34
Moderate Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Day range
Current $16.99
52-week range
Current $16.99
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 172.35M USD | 23.68M USD | — | — | 139.71M USD |
| Cost of goods sold | 6.97M USD | 826K USD | — | — | — |
| Gross profit | 165.38M USD | 22.85M USD | — | — | 139.71M USD |
| Research and development | 258.78M USD | 241.65M USD | 163.03M USD | 118.5M USD | 88.25M USD |
| Selling, general, and administrative | 179.68M USD | 120.88M USD | 66.92M USD | 33.26M USD | 25.24M USD |
| Operating expenses | 438.47M USD | 362.53M USD | 229.95M USD | 151.76M USD | 113.49M USD |
| Interest income | 22.73M USD | 26.09M USD | 21.16M USD | 5.87M USD | 403K USD |
| Interest expense | 33.79M USD | 4.93M USD | 208K USD | 3.14M USD | 1.9M USD |
| Depreciation and amortization | 6K USD | 8K USD | 12K USD | 33K USD | 43K USD |
| Operating income | −273.08M USD | −339.67M USD | −229.95M USD | −151.76M USD | 26.22M USD |
| Net income | −285.42M USD | −318.76M USD | −209.36M USD | −149.34M USD | 24.93M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$36.67
115.83% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI54.68M0.00%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI44.66M0.44%10.11B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM39.45M0.05%77.7B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF19.89M0.02%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO13.87M0.10%14.04B USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB10.69M0.10%10.41B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO9.87M0.05%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA8.05M0.04%21.73B USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
